A magneto-optic route toward the in vivo diagnosis of malaria: preliminary results and preclinical trial data

D.M. Newman, J. Heptinstall, R.J. Matelon, L. Savage, M.L. Wears, Jamie Beddow, Martin Cox, H.D.F.H. Schallig, P.F. Mens

    Research output: Contribution to journalArticle

    83 Citations (Scopus)

    Abstract

    We report the development of magneto-optic technology for the rapid quantitative diagnosis of malaria that may also be realizable in a noninvasive format. Hemozoin, the waste product of malarial parasitic action on hemoglobin, is produced in a form that under the action of an applied magnetic field gives rise to an induced optical dichroism characteristic of the hemozoin concentration. Here we show that precise measurement of this induced dichroism may be used to determine the level of malarial infection because this correlates, albeit in a complex manner throughout the infection cycle, with the concentration of hemozoin in the blood and tissues of infected patients. Under conservative assumptions for the production of hemozoin as a function of parasitemia, initial results indicate that the technique can match or exceed other current diagnostic techniques. The validity of the approach is confirmed by a small preliminary clinical trial on 13 patients, and measurements on live parasitized cells obtained from in vitro culture verify the possibility of producing in vivo diagnostic instrumentation.
    Original languageEnglish
    Pages (from-to)994-1000
    JournalBiophysical Journal
    Volume95
    Issue number2
    DOIs
    Publication statusPublished - Jul 2008

    Bibliographical note

    The full text is available free from the link given. The published version can be found at: http://dx.doi.org/10.1529/biophysj.107.128140

    Keywords

    • magneto-optic technology
    • diagnosis
    • malaria
    • hemozoin
    • biological markers

    Fingerprint

    Dive into the research topics of 'A magneto-optic route toward the in vivo diagnosis of malaria: preliminary results and preclinical trial data'. Together they form a unique fingerprint.

    Cite this